Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) EBT (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed EBT for 16 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 18.82% to -$1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.0 million, a 12.1% decrease, with the full-year FY2024 number at -$5.5 million, down 3.91% from a year prior.
  • EBT was -$1.2 million for Q3 2025 at Creative Medical Technology Holdings, roughly flat from -$1.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $27.8 million in Q1 2021 to a low of -$6.2 million in Q4 2022.
  • A 5-year average of -$306298.2 and a median of -$1.5 million in 2023 define the central range for EBT.
  • Biggest YoY gain for EBT was 643.79% in 2021; the steepest drop was 566.91% in 2021.
  • Creative Medical Technology Holdings' EBT stood at -$3.9 million in 2021, then crashed by 60.39% to -$6.2 million in 2022, then surged by 72.99% to -$1.7 million in 2023, then decreased by 10.46% to -$1.9 million in 2024, then surged by 33.34% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CELZ's EBT are -$1.2 million (Q3 2025), -$1.2 million (Q2 2025), and -$1.6 million (Q1 2025).